Pcsk 9 Sirna denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This Claim — and Why You Can Appeal

Cigna's quantity-limit denial for a PCSK9 siRNA therapy means the amount or frequency prescribed exceeds what Cigna's formulary permits without additional authorization. PCSK9 siRNA agents are typically dosed on a specific administration schedule set out in the FDA-approved prescribing label — verify the exact labeled dosing schedule. If your prescriber has ordered the drug on a schedule consistent with the FDA label and Cigna's limit is more restrictive, that discrepancy is central to your appeal. Quantity limits can also be appealed when a patient's clinical situation — for example, a documented need for more frequent monitoring or a body-weight or pharmacokinetic factor documented in the chart — supports a different dosing approach.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written appeal within the deadline on your denial notice. Quantity-limit denials are subject to the same full-and-fair review requirement as any other adverse coverage determination.
• External review (ACA §2719): If the internal appeal is denied, you have approximately four months from the final internal denial to file with an independent external review organization.
• Expedited review: Available if the standard timeline would seriously jeopardize health or ability to regain maximum function.

## Documentation to Gather

1. FDA prescribing label — print the current label and highlight the approved dosing frequency and administration schedule. If Cigna's quantity limit is below the FDA-approved regimen, this is your primary argument. 2. Prescriber's medical-necessity letter — your physician should explain, in clinical terms, why the prescribed quantity is necessary and consistent with the label and with the applicable ACC/AHA or similar cardiovascular guideline. 3. Clinical chart documentation — notes showing your diagnosis, cardiovascular risk profile, current lipid values (from chart), and any factors that affect dosing decisions. 4. Cigna's quantity-limit policy — request the specific coverage policy in writing so you can respond to the exact limit being applied. 5. Prior authorization correspondence — any previous approvals or denials and their stated rationale.

## Criteria-Mapping Structure for Your Appeal Letter

| Cigna quantity-limit basis | Your response | |---|---| | Prescribed quantity exceeds plan limit | FDA label confirms the prescribed schedule is the labeled regimen | | No documented clinical justification for quantity | Prescriber letter + chart notes documenting clinical rationale | | Step-edit required before full quantity | Evidence of prior therapies tried (if applicable) |

Conclusion your appeal should reach: the prescribed quantity is the FDA-labeled dose and schedule; restricting it below the labeled regimen is a coverage limitation inconsistent with medically accepted standards, and you request a clinical peer-to-peer review if the initial appeal is upheld.